Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions
NCT ID: NCT02312297
Last Updated: 2014-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2008-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the course of the study, safety parameters assessed were vital signs, clinical examination, medical history and clinical laboratory safety tests (hematology, biochemical parameters, serology and urine analysis) at baseline. Adverse event monitoring was done throughout the study. Laboratory parameters of hematology and biochemistry (except blood glucose and cholesterol) were repeated at the end of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test
Minocycline hydrochloride extended release tablets 135 mg
Minocycline hydrochloride
extended release tablets 135 mg
Reference
Solodyn Extended Release Tablets 135 mg
Minocycline hydrochloride
extended release tablets 135 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minocycline hydrochloride
extended release tablets 135 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Were in the age range of 18-45 years
2. Were neither overweight nor underweight for their height as per the Life Insurance Corporation of India height/weight chart for non-medical cases
3. Had voluntarily given written informed consent to participate in this study
4. Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study
5. Male subjects and:
* Whose female partner(s) was/were not pregnant or was/were not planning to become pregnant
* Whose female partner(s) was/were using at least one highly effective and one acceptable method of birth control (at the same time) for the duration of the study and for 2 weeks after completion of the study, such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence. Dual method of contraception must be used during the study and for 2 weeks after its discontinuation
* Whose female partner was surgically sterile (bilateral tubal ligation, bilateral oophorectomy, hysterectomy)
* Those using condoms even if vasectomy has been done; during the study and for 2 weeks after completion of the study
Exclusion Criteria
2. History of diarrhoea in last one week or antibiotic induced diarrhoea
3. Frequent episodes of light headedness, vertigo and dizziness preceding one week
4. History of photosensitivity
5. Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations
6. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma, head-injury or coma
7. History of any psychiatric illness, which may impair the ability to provide written informed consent
8. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection
9. Presence of values which are out of acceptable limits for haemoglobin, total white blood cells count, differential WBC count or platelet count
10. Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids)
11. Presence of values which are out of acceptable limits for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol
12. Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (\> 4/HPF), glucose (positive) or protein (positive)
13. Clinically abnormal ECG or Chest X-ray
14. Regular smokers who smoked more than 10 cigarettes daily or had difficulty abstaining from smoking for the duration of each study period
15. History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period
16. Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study
17. Participation in any clinical trial within 12 weeks preceding Day 1 of this study
18. Subjects who, through completion of this study, would have donated and /or lost more than 350 ml of blood in the past 3 months other than study participation
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ranbaxy Laboratories Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
237_MINOC_08
Identifier Type: -
Identifier Source: org_study_id